Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805023 · ClinicalTrials.gov registry record · Phase 1
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
A Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease, sponsored by BioGenCell.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT02805023 is a Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease that is active but no longer recruiting, run by BioGenCell. The registered enrollment target is 40 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02805023, a Phase 1 study of Peripheral Arterial Disease and Peripheral Vascular Disease, is active but no longer recruiting, sponsored by BioGenCell.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.
Conditions Studied
Interventions
- BIOLOGICAL BGC101 (autologous EnEPC preparation)
- BIOLOGICAL Control medium
Study Locations (5)
Other
- Rambam Health Care Campus - Haifa
- Laniado Hospital - Netanya
California
- University of San Francisco - San Francisco
Connecticut
- Yale University School of Medicine - New Haven
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02805023
The ClinicalTrials.gov registry entry for NCT02805023 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The listed sponsor is BioGenCell, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which BGC101 (autologous EnEPC preparation) is the first listed.
NCT02805023 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02805023 about?
NCT02805023 is a clinical study titled "BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)". Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with c...
What is the current status of trial NCT02805023?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-06. Estimated completion is 2027-12.
What conditions does trial NCT02805023 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Chronic Limb-Threatening Ischemia.
What interventions are being tested in trial NCT02805023?
The interventions under investigation include: BGC101 (autologous EnEPC preparation) (BIOLOGICAL), Control medium (BIOLOGICAL).
Who is sponsoring clinical trial NCT02805023?
This trial is sponsored by BioGenCell, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02805023 being conducted?
This trial has 5 study locations across California, Connecticut, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
RECRUITING · Phase 1
-
Carnosine for Peripheral Arterial Disease Patients
RECRUITING · Phase 1
-
Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
COMPLETED · Phase 1
-
Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)
COMPLETED · Phase 1
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
ALD-301 for Critical Limb Ischemia, Randomized Trial
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.